Thalassemia
alpha-Thalassemia
alpha-Globins
Globins
Hemoglobinopathies
Hemoglobins, Abnormal
Fetal Hemoglobin
beta-Thalassemia
Reticulocytes
Hemoglobin E
Chelation Therapy
Iron Overload
Iron Chelating Agents
Hemoglobin A2
Blood Transfusion
Deferoxamine
beta-Globins
Anemia, Sickle Cell
alpha 1-Antitrypsin
Hemoglobin H
Hemoglobin J
Iron
Erythrocytes, Abnormal
Receptors, Adrenergic, alpha
Ferritins
Heterozygote
Hemoglobins
Hypoxia-Inducible Factor 1, alpha Subunit
Hemoglobin A
Erythrocyte Indices
Hemosiderosis
Base Sequence
delta-Thalassemia
Erythropoiesis
alpha7 Nicotinic Acetylcholine Receptor
Hemoglobin, Sickle
Erythrocytes
Mutation
Integrin alpha3beta1
A complex haemoglobinopathy diagnosis in a family with both beta zero- and alpha (zero/+)-thalassaemia homozygosity. (1/248)
The occurrence of point mutation alpha-thalassaemia and of complex combinations of haemoglobin defects is underestimated. Haemoglobinopathies, the most frequent monogenic recessive autosomal disorder in man, occur predominantly in Mediterranean, African and Asiatic populations. However, countries of immigration with a low incidence in the indigenous population, are now confronted with a highly heterogeneous array of imported defects. Furthermore, the occurrence of severe phenotypes is bound to increase in the near future because of the endogamous growth of the ethnical minorities and the lack of prevention. We describe an Afghan family in which both partners of a consanguineous relationship are carriers of a beta- as well as an alpha-thalassaemia determinant. The combination of defects was revealed by the in vitro measurement of the beta/alpha biosynthetic ratio and was characterised at the DNA level. The molecular defects involved are the Cd5(-CT), a Mediterranean beta zero-thalassaemia mutation, and the alpha 2(zero/+)-thalassaemia AATA(-AA) polyadenylation defect. The alpha-thalassemia defect is a rare RNA-processing mutant described only twice before in heterozygous form in Asian-Indian patients. The mutation suppresses the expression of a alpha 2 gene and reduces the expression of the less efficient, 3' located alpha 1 gene as well, inducing a near alpha zero-thalassaemia phenotype. This defect is now described for the first time in the homozygous condition in one of the children who, in addition to being homozygous for the alpha-thalassaemia point mutation, is also a carrier of the beta zero-thalassaemia defect. A previously described homozygous case of the alpha (zero/+)-thalassaemia condition, caused by a similar polyadenylation defect, was characterised by a severe HbH disease. However, the patient described here present at 7 years of age with severe caries, like his beta-thalassaemia homozygous brother but without hepatosplenomegaly, haemolysis or severe anaemia. The haematological analysis revealed 9.5 g/dl Hb; 5.4 x 10(12)/I RBC; 0.33 I/I PCV; 61 fl MCV; 17.6 pg MCH and 6.2% of HbA2. The biosynthetic ratio beta:alpha was 1.6 and no HbH fraction was detectable either on electrophoresis or as inclusion bodies. The parents reported no complications during pregnancy, at birth, or in the neonatal period in rural Afghanistan. We presume therefore that the counterbalancing effect induced by the co-existing beta-thalassaemia defect could have modified a potentially severe perinatal HbH disease into a strongly hypochromic but well compensated 'alpha zero-like heterozygous' thalassaemia phenotype. The risk of a severe HbH disease, could have been easily missed in this family which was referred because of a child affected with beta-thalassaemia major. (+info)Cardiac blood flow studies in fetuses with homozygous alpha-thalassemia-1 at 12-13 weeks of gestation. (2/248)
OBJECTIVE: Fetuses affected by homozygous alpha-thalassemia-1 develop anemia as early as the first trimester. Our objective was to study hemodynamic indices in affected fetuses at 12-13 weeks of gestation to determine whether these would be useful in the prediction of anemia. DESIGN: Prospective observational study. SUBJECTS: Women referred before 14 weeks of gestation for the prenatal diagnosis of homozygous alpha-thalassemia-1. METHODS: Transabdominal and/or transvaginal Doppler sonography was performed to measure the flow velocities in the fetal ascending aorta and pulmonary artery at 12-13 weeks. The Doppler indices were compared between those that were subsequently confirmed to be affected by homozygous alpha-thalassemia-1 and those that were unaffected. RESULTS: Between June 1997 and April 1998, 60 eligible women were recruited. Doppler examination was successful in 58 fetuses. Of these, 22 were subsequently confirmed to be affected by homozygous alpha-thalassemia-1. The diagnosis was made by chorionic villus sampling and DNA analysis in two affected fetuses and by cordocentesis and hemoglobin evaluation in 20 affected fetuses. Hemoglobin concentrations could be measured in ten fetuses and these ranged from 4 to 8 g/dl. The affected fetuses had significantly higher peak velocities at the pulmonary valve and ascending aorta and a larger inner diameter of the pulmonary valve than that in unaffected fetuses. The total cardiac output was increased by one-third in affected fetuses and was mainly due to an increase of the right-side cardiac output. CONCLUSION: In the early stage of anemia, the fetus responds mainly by increasing its right-side cardiac output. However, there is extensive overlap of the values of cardiac output between the affected and the unaffected fetuses, precluding its use in the prediction of anemia. (+info)Evaluation of a mutation screening strategy for sporadic cases of ATR-X syndrome. (3/248)
We report on the evaluation of a strategy for screening for XNP/ATR-X mutations in males with mental retardation and associated dysmorphology. Because nearly half of the mutations in this gene reported to date fall into a short 300 bp region of the transcript, we decided to focus in this region and to extend the mutation analysis to cases with a negative family history. This study includes 21 mentally retarded male patients selected because they had severe mental retardation and a typical facial appearance. The presence of haemoglobin H or urogenital abnormalities was not considered critical for inclusion in this study. We have identified six mutations which represents a mutation detection rate of 28%. This figure is high enough for us to propose this strategy as a valid first level of screening in a selected subset of males with mental retardation. This approach is simple, does not require RNA preparation, does not involve time consuming mutation detection methods, and can thus be applied to a large number of patients at a low cost in any given laboratory. (+info)Intrathoracic extramedullary haematopoiesis complicated by massive haemothorax in alpha-thalassaemia. (4/248)
Intrathoracic extramedullary haematopoiesis (EMH) is a rare entity that is usually asymptomatic. A 44 year old man with alpha-thalassaemia is described who developed dyspnoea and massive left sided haemothorax. The haemoglobin disorder was established by Hgb H staining and haemoglobin electrophoretic studies. The DNA analysis revealed it to be a case of double heterozygous terminal codon mutation with the genotype alphaalphaCS/alphaalphaT. Computed tomographic scanning and magnetic resonance imaging of the thorax showed multiple paravertebral masses which were found by thoracoscopic biopsy to be extramedullary haematopoiesis. Although no additional sclerosing pleurodesis or low dose radiation therapy was given, the lung expanded well and there has been no recurrence of haemothorax to date. (+info)Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry. (5/248)
Certain red blood cell (RBC) disorders, including thalassemia, have been associated with an innate protection against malaria infection. However, many in vitro correlative studies have been inconclusive. To better understand the relationship between human RBCs with thalassemia hemoglobinopathies and susceptibility to in vitro infection, we used an in vitro coculture system that involved biotin labeling and flow cytometry to study the ability of normal and variant RBC populations in supporting the growth of Plasmodium falciparum malaria parasites. Results showed that both normal and thalassemic RBCs were susceptible to P falciparum invasion, but the parasite multiplication rates were significantly reduced in the thalassemic RBC populations. The growth inhibition was especially marked in RBCs from alpha-thalassemia patients (both alpha-thalassemia1/alpha-thalassemia2 and alpha-thalassemia1 heterozygote). Our observations support the contention that thalassemia confers protection against malaria and may explain why it is more prevalent in malaria endemic areas. (+info)The contribution of alpha+-thalassaemia to anaemia in a Nigerian population exposed to intense malaria transmission. (6/248)
The proportion to which alpha-thalassaemia contributes to anaemia in Africa is not well recognized. In an area of intense malaria transmission in South-West Nigeria, haematological parameters of alpha-thalassaemia were examined in 494 children and 119 adults. The -alpha3.7 type of alpha+-thalassaemia was observed at a gene frequency of 0.27. Nine and 36.5% of individuals were homozygous and heterozygous, respectively. P.falciparum-infection was present in 78% of children and in 39% of adults. The alpha-globin genotypes did not correlate with the prevalence of P. falciparum-infection. alpha+-thalassaemic individuals had significantly lower mean values of haemoglobin, mean corpuscular volume, and mean corpuscular haemoglobin than non-thalassaemic subjects. Anaemia was seen in 54. 7% of children with a normal alpha-globin genotype, in 69.9% of heterozygous (odds ratio: 1.99, 95% confidence interval: 1.32-3.00, P = 0.001), and in 88.4% of homozygous alpha+-thalassaemic children (odds ratio: 7.72, 95% confidence interval: 2.85-20.90, P = 0.0001). The findings show that alpha+-thalassaemia contributes essentially to mild anaemia, microcytosis, and hypochromia in Nigeria. (+info)A normal beta-globin allele as a modifier gene ameliorating the severity of alpha-thalassemia in mice. (7/248)
Thalassemia is a heritable human anemia caused by a variety of mutations that affect expression of the alpha- or the beta-chain of hemoglobin. The expressivity of the phenotype is likely to be influenced by unlinked modifying genes. Indeed, by using a mouse model of alpha-thalassemia, we find that its phenotype is strongly influenced by the genetic background in which the alpha-thalassemia mutation resides [129(sv/ev)/129(sv/ev) (severe) or 129(sv/ev)/C57BL/6 (mild)]. Linkage mapping indicates that the modifying gene is very tightly linked to the beta-globin locus (Lod score = 13.3). Furthermore, the severity of the phenotype correlates with the size of beta-chain-containing inclusion bodies that accumulate in red blood cells and likely accelerate their destruction. The beta-major globin chains encoded by the two strains differ by three amino acids, one of which is a glycine-to-cysteine substitution at position 13. The Cys-13 should be available for interchain disulfide bridging and consequent aggregation between excess beta-chains. This normal polymorphic variation between murine beta-globin chains could account for the modifying action of the unlinked beta-globin locus. Here, the variation in severity of the phenotype would not depend on a change in the ratio between alpha- and beta-chains but on the chemical nature of the normal beta-chain, which is in excess. This work also indicates that modifying genes can be normal variants that-absent an apparent physiologic rationale-may be difficult to identify on the basis of structure alone. (+info)Nuchal translucency in fetuses affected by homozygous alpha-thalassemia-1 at 12-13 weeks of gestation. (8/248)
OBJECTIVE: Fetuses affected by homozygous alpha-thalassemia-1 are anemic in the first trimester. We studied their nuchal translucency (NT) measurements at 12-13 weeks of gestation. METHODS: Nuchal translucency was measured prospectively in fetuses at risk of homozygous alpha-thalassemia-1. Measurements of those fetuses subsequently confirmed to be affected by homozygous alpha-thalassemia-1 but with a normal karyotype were compared to those of 440 controls. The controls were from the general obstetric population who had NT measurements at 12 or 13 weeks with known normal outcome. All the NT measurements were expressed as multiples of the median (MoM) for the gestational day. RESULTS: Between 1996 and 1998, 94 at-risk pregnancies were studied. Of these, 32 were subsequently confirmed to be affected by homozygous alpha-thalassemia-1. Chromosome study was not carried out in three cases and these were excluded from the analysis. Nuchal translucency MoMs for cases and controls were found to fit a log Gaussian distribution. The log means (standard deviation) for case and control NT MoM were 0.075 (0.156) and -0.0019 (0.091), respectively. The median NT MoM (95% CI) for cases was 1.19 (1.08-1.62) and was significantly higher than that of the controls (p < 0.001). However, there was extensive overlap of NT between cases and controls. CONCLUSION: Overall, there was a 19% increase in NT MoM in fetuses affected by homozygous alpha-thalassemia-1. This represents a difference of only 0.3-0.4 mm, which is clinically insignificant. This finding indirectly suggests that the increased NT in trisomic fetuses cannot be explained by fetal anemia. Conversely, the presence of increased NT in a fetus at risk of homozygous alpha-thalassemia-1 should alert one to the possibility of chromosomal abnormality rather than being attributed to fetal anemia. (+info)There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia. Alpha-thalassemia is caused by abnormalities in the production of the alpha-globin chain, which is one of the two chains that make up hemoglobin. Beta-thalassemia is caused by abnormalities in the production of the beta-globin chain.
Thalassemia can cause a range of symptoms, including anemia, fatigue, pale skin, and shortness of breath. In severe cases, it can lead to life-threatening complications such as heart failure, liver failure, and bone deformities. Thalassemia is usually diagnosed through blood tests that measure the levels of hemoglobin and other proteins in the blood.
There is no cure for thalassemia, but treatment can help manage the symptoms and prevent complications. Treatment may include blood transfusions, folic acid supplements, and medications to reduce the severity of anemia. In some cases, bone marrow transplantation may be recommended.
Preventive measures for thalassemia include genetic counseling and testing for individuals who are at risk of inheriting the disorder. Prenatal testing is also available for pregnant women who are carriers of the disorder. In addition, individuals with thalassemia should avoid marriage within their own family or community to reduce the risk of passing on the disorder to their children.
Overall, thalassemia is a serious and inherited blood disorder that can have significant health implications if left untreated. However, with proper treatment and management, individuals with thalassemia can lead fulfilling lives and minimize the risk of complications.
There are two main forms of alpha-Thalassemia:
1. Alpha-thalassemia major (also known as Hemoglobin Bart's hydrops fetalis): This is a severe form of the disorder that can cause severe anemia, enlarged spleen, and death in infancy. It is caused by a complete absence of one or both of the HBA1 or HBA2 genes.
2. Alpha-thalassemia minor (also known as Hemoglobin carrier state): This form of the disorder is milder and may not cause any symptoms at all. It is caused by a partial deletion of one or both of the HBA1 or HBA2 genes.
People with alpha-thalassemia minor may have slightly lower levels of hemoglobin and may be more susceptible to anemia, but they do not typically experience any severe symptoms. Those with alpha-thalassemia major, on the other hand, are at risk for serious complications such as anemia, infections, and organ failure.
There is no cure for alpha-thalassemia, but treatment options include blood transfusions, iron chelation therapy, and management of associated complications. Screening for alpha-thalassemia is recommended for individuals who are carriers of the disorder, as well as for those who have a family history of the condition.
The most common types of hemoglobinopathies include:
1. Sickle cell disease: This is caused by a point mutation in the HBB gene that codes for the beta-globin subunit of hemoglobin. It results in the production of sickle-shaped red blood cells, which can cause anemia, infections, and other complications.
2. Thalassemia: This is a group of genetic disorders that affect the production of hemoglobin and can result in anemia, fatigue, and other complications.
3. Hemophilia A: This is caused by a defect in the F8 gene that codes for coagulation factor VIII, which is essential for blood clotting. It can cause bleeding episodes, especially in males.
4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: This is caused by a point mutation in the G6PD gene that codes for an enzyme involved in red blood cell production. It can cause hemolytic anemia, especially in individuals who consume certain foods or medications.
5. Hereditary spherocytosis: This is caused by point mutations in the ANK1 or SPTA1 genes that code for proteins involved in red blood cell membrane structure. It can cause hemolytic anemia and other complications.
Hemoglobinopathies can be diagnosed through genetic testing, such as DNA sequencing or molecular genetic analysis. Treatment options vary depending on the specific disorder but may include blood transfusions, medications, and in some cases, bone marrow transplantation.
There are two main types of beta-thalassemia:
1. Beta-thalassemia major (also known as Cooley's anemia): This is the most severe form of the condition, and it can cause serious health problems and a shortened lifespan if left untreated. Children with this condition are typically diagnosed at birth or in early childhood, and they may require regular blood transfusions and other medical interventions to manage their symptoms and prevent complications.
2. Beta-thalassemia minor (also known as thalassemia trait): This is a milder form of the condition, and it may not cause any noticeable symptoms. People with beta-thalassemia minor have one mutated copy of the HBB gene and one healthy copy, which allows them to produce some normal hemoglobin. However, they may still be at risk for complications such as anemia, fatigue, and a higher risk of infections.
The symptoms of beta-thalassemia can vary depending on the severity of the condition and the age of onset. Common symptoms include:
* Fatigue
* Weakness
* Pale skin
* Shortness of breath
* Frequent infections
* Yellowing of the skin and eyes (jaundice)
* Enlarged spleen
Beta-thalassemia is most commonly found in people of Mediterranean, African, and Southeast Asian ancestry. It is caused by mutations in the HBB gene, which is inherited from one's parents. There is no cure for beta-thalassemia, but it can be managed with blood transfusions, chelation therapy, and other medical interventions. Bone marrow transplantation may also be a viable option for some patients.
In conclusion, beta-thalassemia is a genetic disorder that affects the production of hemoglobin, leading to anemia, fatigue, and other complications. While there is no cure for the condition, it can be managed with medical interventions and bone marrow transplantation may be a viable option for some patients. Early diagnosis and management are crucial in preventing or minimizing the complications of beta-thalassemia.
Symptoms of iron overload can include fatigue, weakness, joint pain, and abdominal discomfort. Treatment for iron overload usually involves reducing iron intake and undergoing regular phlebotomy (blood removal) to remove excess iron from the body. In severe cases, iron chelation therapy may be recommended to help remove excess iron from tissues and organs.
In addition to these medical definitions and treatments, there are also some key points to keep in mind when it comes to iron overload:
1. Iron is essential for human health, but too much of it can be harmful. The body needs a certain amount of iron to produce hemoglobin, the protein in red blood cells that carries oxygen throughout the body. However, excessive iron levels can damage organs and tissues.
2. Hereditary hemochromatosis is the most common cause of iron overload. This genetic disorder causes the body to absorb too much iron from food, leading to its accumulation in organs and tissues.
3. Iron overload can increase the risk of certain diseases, such as liver cirrhosis, diabetes, and heart disease. It can also lead to a condition called hemosiderosis, which is characterized by the deposition of iron in tissues and organs.
4. Phlebotomy is a safe and effective treatment for iron overload. Regular blood removal can help reduce excess iron levels and prevent complications such as liver damage, heart failure, and anemia.
5. Iron chelation therapy may be recommended in severe cases of iron overload. This involves using drugs to remove excess iron from tissues and organs, but it is not always necessary and can have potential side effects.
Sickle cell anemia is caused by mutations in the HBB gene that codes for hemoglobin. The most common mutation is a point mutation at position 6, which replaces the glutamic acid amino acid with a valine (Glu6Val). This substitution causes the hemoglobin molecule to be unstable and prone to forming sickle-shaped cells.
The hallmark symptom of sickle cell anemia is anemia, which is a low number of healthy red blood cells. People with the condition may also experience fatigue, weakness, jaundice (yellowing of the skin and eyes), infections, and episodes of severe pain. Sickle cell anemia can also increase the risk of stroke, heart disease, and other complications.
Sickle cell anemia is diagnosed through blood tests that measure hemoglobin levels and the presence of sickle cells. Treatment typically involves managing symptoms and preventing complications with medications, blood transfusions, and antibiotics. In some cases, bone marrow transplantation may be recommended.
Prevention of sickle cell anemia primarily involves avoiding the genetic mutations that cause the condition. This can be done through genetic counseling and testing for individuals who have a family history of the condition or are at risk of inheriting it. Prenatal testing is also available for pregnant women who may be carriers of the condition.
Overall, sickle cell anemia is a serious genetic disorder that can significantly impact quality of life and life expectancy if left untreated. However, with proper management and care, individuals with the condition can lead fulfilling lives and manage their symptoms effectively.
Sickle cell trait is relatively common in certain populations, such as people of African, Mediterranean, or Middle Eastern descent. It is estimated that about 1 in 12 African Americans carry the sickle cell gene, and 1 in 500 are homozygous for the trait (meaning they have two copies of the sickle cell gene).
Although people with sickle cell trait do not develop sickle cell anemia, they can experience certain complications related to the trait. For example, they may experience episodes of hemolytic crisis, which is a condition in which red blood cells are destroyed faster than they can be replaced. This can occur under certain conditions, such as dehydration or infection.
There are several ways that sickle cell trait can affect an individual's life. For example, some people with the trait may experience discrimination or stigma based on their genetic status. Additionally, individuals with sickle cell trait may be more likely to experience certain health problems, such as kidney disease or eye damage, although these risks are generally low.
There is no cure for sickle cell trait, but it can be managed through proper medical care and self-care. Individuals with the trait should work closely with their healthcare provider to monitor their health and address any complications that arise.
Overall, sickle cell trait is a relatively common genetic condition that can have significant implications for an individual's life. It is important for individuals with the trait to understand their risk factors and take steps to manage their health and well-being.
The main symptoms of hemosiderosis include:
1. Yellowish discoloration of the skin and eyes (jaundice)
2. Fatigue, weakness, and shortness of breath
3. Abdominal pain, nausea, and vomiting
4. Pale or clay-colored stools
5. Dark urine
6. Liver enlargement and tenderness
7. Heart failure
8. Arrhythmias (irregular heart rhythms)
9. Anemia
10. Weight loss and loss of appetite
Hemosiderosis is diagnosed through a combination of physical examination, medical history, laboratory tests, and imaging studies such as ultrasound, CT scan, or MRI. Treatment options for hemosiderosis depend on the underlying cause of the condition and may include:
1. Iron chelation therapy to remove excess iron from the body
2. Blood transfusions to reduce iron levels
3. Dietary modifications to limit iron intake
4. Medications to manage symptoms such as anemia, liver failure, or heart problems
5. Surgery to remove affected tissues or organs in severe cases
It is important to seek medical attention if you experience any of the symptoms of hemosiderosis, especially if you have a history of excessive iron intake or chronic blood transfusions. Early diagnosis and treatment can help prevent complications and improve outcomes for this condition.
Delta-Thalassemia is classified into two main types: delta-plus-thalassemia and delta-beta-thalassemia. Delta-plus-thalassemia is the more severe form of the disorder and is characterized by a complete absence of delta-globin chain production, resulting in severe anemia and often death before the age of two. Delta-beta-thalassemia is a milder form of the disorder and is characterized by reduced production of delta-globin chains, which can lead to mild anemia or no anemia at all.
Delta-Thalassemia is inherited in an autosomal recessive pattern, meaning that a child must inherit two copies of the mutated HBB gene (one from each parent) to develop the disorder. Carriers of the disorder, who have one normal copy of the HBB gene and one mutated copy, are generally asymptomatic but can pass the mutated gene to their children.
There is currently no cure for delta-Thalassemia, but treatment options include blood transfusions, folic acid supplements, and bone marrow transplantation. The prognosis for patients with delta-Thalassemia depends on the severity of the disorder and can vary from mild to severe.
Alpha-thalassemia
Thalassemia
Antisense RNA
Heinz body
List of OMIM disorder codes
Delta-beta thalassemia
Hemoglobin subunit beta
Hemoglobin Barts
ATR-X syndrome
ATRX
Hemoglobin H disease
PBDC1
Epigenetics of human development
Hydrops fetalis
Hemoglobin, alpha 2
ATR-16 syndrome
Hemoglobinopathy
Hemoglobin subunit alpha
Hemoglobin electrophoresis
Hemoglobin A
ERAF
Yuet Wai Kan
Kath Maitland
Hemoglobin Constant Spring
Tharu people
Hemoglobin subunit zeta
HBAP1
List of hematologic conditions
Sickle cell trait
Beta thalassemia
Promoter (genetics)
Embryonic hemoglobin
Jan Aaseth
HBD
Chromosome 16
Mirror syndrome
Hepcidin
Chelation therapy
Hemoglobin O
High Resolution Melt
Ranbir Chander Sobti
HBG2
Genetic studies on Arabs
Jaundice
Wei-Shau Hu
Sickle cell nephropathy
Contaminated haemophilia blood products
Hemoglobin variants
List of syndromes
Stephen Oppenheimer
Inclusion bodies
Eirini Nikolopoulou
Congenital dyserythropoietic anemia type II
Newborn Screening Practices and Alpha-Thalassemia Detection - United States, 2016 | MMWR
Alpha thalassemia: MedlinePlus Genetics
Beta Thalassaemia, Alpha Thalassaemia and Sickle Cell Disease Educational Community booklet (2014) - TIF
The interaction of alpha thalassaemia with heterozygous beta thalassaemia - Radcliffe Department of Medicine
Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. - MRC Weatherall Institute of...
Parker Ruhl, M.D., M.H.S. | NIH: National Institute of Allergy and Infectious Diseases
Search
WHO EMRO | Thalassaemia genes in Baghdad, Iraq | Volume 2, issue 2 | EMHJ volume 2, 1996
Red Blood cell and Bleeding Disorders.pdf
Ankyrin Mutations in Hereditary Spherocytosis | Acta Haematologica | Karger Publishers
Sickle Cell Disease | WHO | Regional Office for Africa
Mitapivat+Sulfate - 505(b)(2) development and clinical trial profile - geography, diseases, companies
Kallikrein 7 ELISA Kits
Hydrops Fetalis Imaging: Practice Essentials, Magnetic Resonance Imaging, Ultrasonography
Anemia Workup: Approach Considerations, Investigation for Pathogenesis, Evaluation for Blood Loss
Charache, Samuel 2002 - Office of NIH History and Stetten Museum
WikiGenes - Gene Frequency
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer | BioSpace
Current Trends Risks Associated with Human Parvovirus B19 Infection
Search
Hemoglobin Evaluation Reflexive Cascade | Test Fact Sheet
All Posts - The Waiting Room
DeCS
Protein S deficiency: Video, Anatomy & Definition | Osmosis
Nor Hedayah A Bakar | Hilaris SRL
Deletions12
- Alpha-thalassemia typically results from deletions involving the HBA1 and HBA2 genes. (nih.gov)
- Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. (medscape.com)
- Deletions and nondeletion variants in one or more alleles reduce the amount of alpha-globin cells produce. (medlineplus.gov)
- Nondeletion variants tend to reduce alpha-globin more than deletions. (medlineplus.gov)
- Because nondeletion variants are usually more severe than deletions, nondeletion variants in two of the four alpha-globin alleles can result in HbH disease. (medlineplus.gov)
- Mutations and gene deletions causing the various thalassemia genotypes have arisen independently in different populations but have subsequently propagated by means of natural selection. (medscape.com)
- The deletions in the zeta-alpha globin gene cluster in two infants with the hemoglobin Bart's hydrops fetalis syndrome (homozygous alpha thalassemia 1) have been mapped by restriction endonuclease analysis using a zeta-specific probe. (ox.ac.uk)
- These lines of investigation offer an opportunity to explore the long-held observations that alpha globin gene deletions reduce the severity of malaria infection and delay or prevent the vascular complications of sickle cell anemia. (nih.gov)
- The frequency of the most common mutation, the Southeast Asian type of deletion (−− SEA , accounting for 48.54% of all α thalassaemias) was similar to the total of two α + thalassaemia deletions (−α 3.7 and −α 4.2 , accounting for 47.49% of α thalassaemia). (bmj.com)
- Alpha thalassemias are some of the most common genetic deletions. (nih.gov)
- To better understand how alpha globin deletions in healthy people affect blood vessels. (nih.gov)
- Both patients had two α-globin gene deletions (−α3.7/−α3.7), also known as alpha-thalassemia trait, and notably are the only patients in the study with this specific genotype. (businesswire.com)
Types of Alpha-thalassemia3
- Two types of alpha thalassemia can cause health problems. (medlineplus.gov)
- The different types of alpha thalassemia result from the loss or alteration of some or all of these alleles. (medlineplus.gov)
- However, the percentage of Hb Bart's used for thalassemia classification, the types of alpha-thalassemia reported, and the recipients of this information varied widely. (cdc.gov)
Genes34
- Less commonly, changes to the DNA sequence in or near these genes cause alpha thalassemia. (medlineplus.gov)
- Both the HBA1 and HBA2 genes provide instructions for making a protein called alpha-globin, which is a component (subunit) of hemoglobin . (medlineplus.gov)
- Alpha chain synthesis is controlled by four alpha genes, two on each copy of chromosome 16. (osmosis.org)
- And alpha thalassemia is caused by mutations in the alpha genes, most commonly a gene deletion. (osmosis.org)
- If a person has two defective alpha genes, the person has alpha thalassemia minor, which causes mild symptoms. (osmosis.org)
- When these genes are missing or altered, thalassemias occur. (hoacny.com)
- Thalassemias are inherited disorders-that is, they're passed from parents to children through genes. (hoacny.com)
- People who have moderate to severe forms of thalassemia have inherited faulty genes from both parents. (hoacny.com)
- You need four genes (two from each parent) to make enough alpha globin protein chains. (hoacny.com)
- If one or more of the genes is missing, you'll have alpha thalassemia trait or disease. (hoacny.com)
- If you're missing two genes, you have alpha thalassemia trait (also called alpha thalassemia minor). (hoacny.com)
- The alpha globin genes are located on chromosome 16. (hoacny.com)
- A child inherits four alpha globin genes (two from each parent). (hoacny.com)
- In this example, the father is missing two alpha globin genes and the mother is missing one alpha globin gene. (hoacny.com)
- Each child has a 25 percent chance of inheriting two missing genes and two normal genes (thalassemia trait), three missing genes and one normal gene (hemoglobin H disease), four normal genes (no anemia), or one missing gene and three normal genes (silent carrier). (hoacny.com)
- If one or both of these genes are altered, you'll have beta thalassemia. (hoacny.com)
- If both genes are altered, you'll have beta thalassemia intermedia or beta thalassemia major (also called Cooley's anemia). (hoacny.com)
- Each child has a 25 percent chance of inheriting two normal genes (no anemia), a 50 percent chance of inheriting one altered gene and one normal gene (beta thalassemia trait), or a 25 percent chance of inheriting two altered genes (beta thalassemia major). (hoacny.com)
- In case of alpha thalassemia, at least one of the alpha globin genes has an abnormality. (indiatimes.com)
- In beta thalassemia, the beta globin genes are affected. (indiatimes.com)
- One can only prevent thalassemia as it is inherited (passed from parents to children via genes). (indiatimes.com)
- Thalassemia develops when faulty genes prevent your body from making the right amount of alpha globin or beta globin chains. (nih.gov)
- If one or more of the genes is missing, you will have alpha thalassemia, which means your body does not make enough alpha globin protein. (nih.gov)
- If your parents have mutations in the alpha globin or beta globin genes, or in other genes that affect the alpha or beta globin proteins chains, then you can inherit thalassemia. (nih.gov)
- People of South Asian descent are more likely than other groups to have at least two missing alpha globin genes, causing more severe alpha thalassemia (hemoglobin H disease or alpha thalassemia major). (nih.gov)
- The alpha globin genotypes of 55 beta thalassaemia heterozygotes have been determined by restriction endonuclease analysis to identify those with interacting alpha thalassaemia genes. (ox.ac.uk)
- A comparison of the haematological and haemoglobin synthesis findings of individuals with normal alpha genotypes (alpha alpha/alpha alpha) with those with one (-alpha/alpha alpha) or two (-alpha/-alpha) alpha genes deleted shows that the latter two groups have more balanced globin chain synthesis ratios, higher haemoglobin levels, and larger, better haemoglobinized red cells. (ox.ac.uk)
- DNA from a Thai infant lacked the psi alpha 1 gene and both alpha genes, but the zeta genes were present. (ox.ac.uk)
- To estimate the prevalence of thalassaemia genes in Baghdad, a study was made of 502 randomly selected pregnant women attending a major maternity care clinic in the city. (who.int)
- Some studies have focused on the prevalence of thalassaemia genes in some Middle Eastern countries [1-4], but none were from Iraq, in spite of evidence suggesting that thalassaemias are not uncommon among Iraqis [5]. (who.int)
- A comprehensive national survey of the distribution of the sickle-cell [Hb S] gene and thalassaemia genes was initiated in 1982, with more than 30,055 blood samples collected. (who.int)
- Part of the DNA is missing from a group of genes called alpha globin. (nih.gov)
- Alpha thalassemia trait is when someone has only two out of the normal four alpha globin genes. (nih.gov)
- Approximately 5% of the world's population carries trait genes for haemoglobin disorders, mainly, sickle-cell disease and thalassaemia. (who.int)
Trait8
- A loss of two of the four alpha-globin alleles results in alpha thalassemia trait. (medlineplus.gov)
- People with alpha thalassemia trait may have unusually small, pale red blood cells and mild anemia. (medlineplus.gov)
- If both parents are missing at least one alpha-globin allele, their children are at risk of having Hb Bart syndrome, HbH disease, or alpha thalassemia trait. (medlineplus.gov)
- This condition is called beta thalassemia trait or beta thalassemia minor. (hoacny.com)
- A simple blood test called Hb electrophoresis or Hb A2 can indicate whether you are a carrier or have a trait of thalassemia minor. (indiatimes.com)
- a-thalassaemia trait, on the other hand, was diagnosed in five subjects, based on the presence of microcytosis, with normal Hb A 2 and F and normal serum ferritin level (i.e. by exclusion of b- and db-thalassaemia, and iron deficiency as causes of microcytosis). (who.int)
- We are testing for alpha thalassemia trait. (nih.gov)
- Participants may be invited to participate in more research studies, whether or not researchers find that they have alpha thalassemia trait. (nih.gov)
Deletion6
- Yu J, Xie J, Luo L, Li Z. An Alu Element-Mediated 28.5?kb a-Thalassemia Deletion Found in a Chinese Family. (medscape.com)
- A reverse dot-blot method for rapid detection of non-deletion alpha thalassaemia. (medscape.com)
- Most alpha-thalassemias are due to deletion mutations, but there are also less common nondeletion mutations ( 5 ). (cdc.gov)
- Analysis of DNA polymorphisms promises to yield many further population markers, and we report here the distribution of a new alpha-globin gene deletion (-alpha 3.7 III) detected by a restriction enzyme mapping. (ox.ac.uk)
- In addition, two novel mutations that give rise to α thalassaemia, one deletion resulting in β thalassaemia, and a rare deletion (−− THAI allele) previously unreported in mainland China were detected. (bmj.com)
- In the SCD patients the frequency of single alpha-gene deletion [-alpha/alpha alpha] was 0.346, compared to 0.263 in the Hb AA group. (who.int)
Forms of alpha thalassemia1
- Two additional forms of alpha thalassemia are related to a reduced amount of alpha-globin. (medlineplus.gov)
Known as alpha thalassemia1
- this leads to the clinical disease known as alpha thalassemia. (medscape.com)
Hydrops fetalis5
- Alpha-thalassemia: Hb H disease and Hb Barts hydrops fetalis. (medscape.com)
- The more severe type is known as hemoglobin Bart hydrops fetalis syndrome, which is also called Hb Bart syndrome or alpha thalassemia major. (medlineplus.gov)
- This condition is called alpha thalassemia major or hydrops fetalis. (hoacny.com)
- Patients with β thalassaemia major inherit two mutant β globin alleles and develop a fatal anaemia in early childhood if untreated, whereas fetuses with Hb Barts' hydrops fetalis caused by the homozygous α 0 thalassaemia gene (−−/−−) die either in utero or shortly after birth as a result of severe intrauterine anaemia. (bmj.com)
- In addition, most patients with Hb H, which generally results from the combination of one α + thalassaemia (−α/ or α T α/) and one α 0 thalassaemia (−−/) defect, have moderately severe but variable anaemia, except for the rare case of α 0 thalassaemia in combination with a non-deletional α globin gene mutation, which can result in hydrops fetalis. (bmj.com)
Syndromes4
- The alpha thalassemia (α-thalassemia) syndromes are a group of hereditary anemias of varying clinical severity. (medscape.com)
- [ 10 ] Individuals with beta thalassemia syndromes have somewhat better protection against malaria than individuals with alpha thalassemia syndromes. (medscape.com)
- Thalassaemia syndromes are inherited defects in the rate of synthesis of one or more of the globin chains of haemoglobin. (who.int)
- Thalassemia syndromes are caused by an absence or ineffective synthesis of beta globin chains. (biomedcentral.com)
Prevalence2
- Despite a 5% global prevalence, alpha-thalassemia is not a core condition on the United States Recommended Uniform Screening Panel for state newborn screening (NBS) programs. (cdc.gov)
- This study reports the true prevalence of silent α thalassaemia in the southern China population for the first time. (bmj.com)
Genetic9
- Workup in alpha thalassemia relies primarily on laboratory evaluation, hemoglobin electrophoresis, and genetic testing (alpha thalassemia mutations panel). (medscape.com)
- Genetic mutations in the alpha-globin gene cluster on chromosome 16 are responsible for alpha-thalassemia, resulting in inefficient production of red blood cells, which affects organ function and growth and results in anemia and iron overload. (cdc.gov)
- Alpha-thalassemia is a genetic disorder where there's a deficiency in production of the alpha globin chains of hemoglobin, which is the oxygen-carrying protein in red blood cells. (osmosis.org)
- Thalassaemia is a blood-related, genetic disorder. (indiatimes.com)
- Thalassemia is a genetic, blood disorder. (indiatimes.com)
- Simple blood tests can help couples identify the risks of having a child with thalassemia or other genetic disorders. (indiatimes.com)
- Thalassaemia is a good candidate disease for control by preventive genetic programmes in developing countries. (bmj.com)
- 6. Progress toward the genetic treatment of the beta-thalassemias. (nih.gov)
- With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. (businesswire.com)
Example of how alpha thalassemia2
- The picture shows one example of how alpha thalassemia is inherited. (hoacny.com)
- Illustration showing an example of how alpha thalassemia is passed down from parent to child. (nih.gov)
Homozygous1
- 1. Gene therapy for homozygous beta-thalassemia. (nih.gov)
Syndrome4
- Hb Bart syndrome, the most severe form of alpha thalassemia, results from the loss or alteration of all four alpha-globin alleles. (medlineplus.gov)
- Individuals with thalassemia syndrome are most often of African, Asian, Mediterranean, or Middle Eastern descent. (medscape.com)
- Public health data for the United States are lacking, but in California, 1 in 10,000 newborns has an alpha-thalassemia syndrome ( 4 ). (cdc.gov)
- Megaloblastic anemia characterized by microcytosis: Imerslund-Grasbeck Syndrome with coexistent alpha-thalassemia. (stjude.org)
Form of thalassemia3
- This form of thalassemia causes moderate to severe anemia. (hoacny.com)
- In each year, over 50,000 new patients are born with a severe form of thalassemia (beta-thalassemia major and HbE beta thalassemia) worldwide. (biomedcentral.com)
- In many Asian countries, the most common form of thalassemia results from the coinheritance of beta thalassemia and HbE. (biomedcentral.com)
Symptoms3
- When Do Symptoms of Alpha-thalassemia Begin? (nih.gov)
- These individuals typically have no thalassemia-related signs or symptoms. (medlineplus.gov)
- If a person has one defective alpha gene, they're called a silent carrier, because they don't have symptoms, but can still pass the gene to their children. (osmosis.org)
Blood disorder4
- Alpha-thalassemia is a blood disorder that reduces the body's production of hemoglobin. (nih.gov)
- Alpha thalassemia is a fairly common blood disorder worldwide. (medlineplus.gov)
- Thalassemia is an inherited blood disorder that causes your body to produce less hemoglobin than normal. (nih.gov)
- Alpha thalassemia is a blood disorder. (nih.gov)
Genetics1
- You may be more likely to have thalassemia based on your family history and genetics and your race or ethnicity. (nih.gov)
Clinically significant1
- Standardization of screening and reporting might lead to more timely diagnoses and health care services and improved outcomes for persons with a clinically significant alpha-thalassemia. (cdc.gov)
Globin gene8
- A): a new silent ß-globin gene variant found in coexistence with a-thalassemia in a family of African origin. (medscape.com)
- Regulation of human alpha-globin gene expression and alpha-thalassemia. (medscape.com)
- We seek to understand how common structural variants in the human alpha globin gene loci affect expression of alpha globin in the vascular endothelium, alter the arterial response to vasoactive stimuli, and modify susceptibility to vascular complications of chronic and infectious diseases. (nih.gov)
- 2. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. (nih.gov)
- 4. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. (nih.gov)
- 8. Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease. (nih.gov)
- 11. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. (nih.gov)
- 12. Current status of globin gene therapy for the treatment of beta-thalassaemia. (nih.gov)
Carrier4
- Nondeletion variants in one or two alleles cause a range of conditions, from alpha thalassemia silent carrier to HbH disease, depending on the allele involved. (medlineplus.gov)
- If one of the parents is a carrier, the child develops thalassemia minor. (indiatimes.com)
- If someone in your family has thalassemia, you may be a carrier. (nih.gov)
- Due to extreme heterogeneity, an uneven frequency of beta thalassemia heterozygote or carrier in the range of 1 and 10% has been reported throughout different parts of India [ 2 ]. (biomedcentral.com)
Single-gene disorders3
- Thalassemia is one of the world's most common single-gene disorders. (medscape.com)
- Thalassemias are the most common single gene disorders ( 2 ), with approximately 5% of the world's population having an alpha-thalassemia variant ( 3 ). (cdc.gov)
- The inherited beta thalassemias including sickle cell anemia and hemoglobin E (HbE) disorders are the most frequent single gene disorders globally [ 1 ]. (biomedcentral.com)
Mutation3
- Melanesians and Polynesians share a unique alpha-thalassemia mutation. (ox.ac.uk)
- The mutation spectrum of α and β thalassaemia and its constitution were fully described in this area. (bmj.com)
- In this comprehensive review, the aim is to to depict the epidemiological aspects of thalassemias, mutation profile and current treatment and management practices in the country by sharing the experience of dealing with 1178 cases over 2009-2014 time periods in a specialized thalassemia treatment centre. (biomedcentral.com)
Clinical3
- A) with Deletional and Nondeletional a + -Thalassemia Mutations: Diverse Hematological and Clinical Features. (medscape.com)
- Standardization of technical and reporting procedures could provide data to better understand the public health impact and clinical outcomes of alpha-thalassemia, ensure appropriate health care, and improve outcomes. (cdc.gov)
- Despite the fact that Bangladesh lies in the world's thalassemia belt, the information on different aspects (epidemiology, clinical course, mortality, complications and treatment outcomes) of thalassemias is lacking. (biomedcentral.com)
Group of inherited disorders1
- Alpha-thalassemia comprises a group of inherited disorders in which alpha-hemoglobin chain production is reduced. (cdc.gov)
Globins1
- There are 4 major types of globins: alpha (α), beta (β), gamma (γ), and delta (δ). (medscape.com)
Anemia2
- Alpha thalassemia combined with sickle-cell anemia results in a higher hemoglobin concentration and improved RBC survival. (medscape.com)
- 9. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. (nih.gov)
Bart's4
- Although alpha-thalassemia is not a core condition of the United States Recommended Uniform Screening Panel* for state newborn screening programs, methodologies used by some newborn screening programs to detect sickle cell disease, which is a core panel condition, also detect a quantitative marker of alpha-thalassemia, hemoglobin (Hb) Bart's, an abnormal type of hemoglobin. (cdc.gov)
- The percentage of Hb Bart's detected correlates with alpha-thalassemia severity. (cdc.gov)
- Because screening platforms vary in their resolution and sensitivity for detection and quantification of aberrant hemoglobin species, using a different platform for the first round of screening compared with the second round maximizes the number of persons identified with Hb Bart's levels indicative of alpha-thalassemia. (cdc.gov)
- Inadequacy of Hb Bart's as an indicator of alpha thalassaemia. (ox.ac.uk)
Haemoglobin4
- And he'd, he's had a funny electrophoresis, because there was some tiny amounts of a funny haemoglobin, which he'd not seen before, and I was just looking at the correspondence the other day, and I wrote back and said, well, could this be a very badly synthesised alpha chain, let's have a look. (webofstories.com)
- The magnitude of the HU-related changes was similar for mean corpuscular volume (MCV) (no α-thalassaemia 13 fl and α-thalassaemia 13 fl) and mean corpuscular haemoglobin (MCH) (no α-thalassaemia 4 pg and α-thalassaemia 4 pg) in both groups. (nih.gov)
- Total haemoglobin increased after HU treatment in both groups, but the increase was smaller and not statistically significant in patients with α-thalassaemia. (nih.gov)
- The aim in this study was to address this issue, by utilizing electronically measured mean corpuscular volume (MCV), coupled with a battery of confirmatory haemoglobin (Hb) and iron studies [6], to screen and confirm the diagnosis of thalassaemia in an obstetric population attending a major maternity care clinic in central Baghdad. (who.int)
India4
- Alpha thalassaemia in tribal communities of coastal Maharashtra, India. (medscape.com)
- Alpha thalassemia also occurs frequently in people from Mediterranean countries, Africa, the Middle East, India, and Central Asia. (medlineplus.gov)
- India ranks the list when it comes to thalassaemia. (indiatimes.com)
- Most information on thalassemia in South Asia comes from studies conducted in India. (biomedcentral.com)
Screening5
- The Association of Public Health Laboratories' Hemoglobinopathy Workgroup conducted a survey of state newborn screening programs' alpha-thalassemia screening methodologies and reporting and follow-up practices. (cdc.gov)
- Survey findings indicated that 41 of 44 responding programs (93%) report some form of alpha-thalassemia results and 57% used a two-method screening protocol. (cdc.gov)
- To better understand newborn screening programs' alpha-thalassemia screening practices, the Association of Public Health Laboratories' Hemoglobinopathy Workgroup initiated the first nationwide survey of U.S. newborn screening programs in October 2016. (cdc.gov)
- Screening programmes for thalassaemia, based on the detection of low MCVs, could miss cases of the interaction of alpha and beta thalassaemia. (ox.ac.uk)
- The knowledge gained in this study will enable the projected number of pregnancies at risk to be estimated and a screening strategy for control of thalassaemia to be designed in this area. (bmj.com)
Malaria1
- Thalassemia is more prevalent in regions in which malaria is endemic because the RBC phenotype confers some protection against malaria. (medscape.com)
Patients8
- Over four million Indians are thalassemia carriers and more than 1, 00,000 are patients. (indiatimes.com)
- Thalassaemia patients should pursue universal immunisation to prevent exposure from infections. (indiatimes.com)
- Studies on the efficacy of HU in SCA patients with α-thalassaemia have yielded varying results. (nih.gov)
- In contrast, HU-related reduction in VOCs was more pronounced in patients with α-thalassaemia (VOC incidence rate ratio HU/placebo: 0.63 for α-thalassaemia and 0.54 for no α-thalassaemia (P for interaction 0.003). (nih.gov)
- CONCLUSION: Hydroxyurea decreases VOCs in SCA patients with and without α-thalassaemia, and the degree of VOC reduction was more pronounced in the patients with alpha-thalassaemia. (nih.gov)
- A group of Yemeni patients with sickle-cell disease [SCD] and normal Hb AA individuals living in Riyadh were studied to determine the incidence of the alpha-gene molecular defect. (who.int)
- 14. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patients. (nih.gov)
- 20. Impact of β-globin mutations on outcome of matched related donor hematopoietic stem cell transplantation for patients with β-thalassemia major. (nih.gov)
Mild1
- The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. (nih.gov)
Sickle cell4
- However, NBS methodologies used to detect sickle cell disease, reported by all states, also detect alpha-thalassemia. (cdc.gov)
- Publication: Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. (nih.gov)
- He began his tenure-track work on endothelial alpha globin in the NHLBI sickle cell branch in 2014. (nih.gov)
- 17. Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease. (nih.gov)
Prevalent1
- This is found frequently in Melanesians and Polynesians but not in five other populations in which alpha-thalassemia is prevalent. (ox.ac.uk)
Disease3
- HbH disease is usually caused by loss or alteration of three of the four alpha-globin alleles, which sharply reduces the amount of normal alpha-globin produced. (medlineplus.gov)
- A 2016 survey of NBS programs found that although most programs report at least one form of suspected alpha-thalassemia, the methodologies, thresholds used, forms of disease reported, and processes for reporting vary widely. (cdc.gov)
- On World Thalassaemia Day, Dr Rajni Khajuria, Lab Director at Igenomix and former researcher at AIIMS, Delhi, shares why it is important to spread awareness about the disease, and take necessary steps. (indiatimes.com)
Carriers3
- A loss of one alpha-globin allele is found in alpha thalassemia silent carriers. (medlineplus.gov)
- Overall, 11.07% of the population in this area were heterozygous carriers of α and β thalassaemia. (bmj.com)
- Most conservative estimates suggest that at least 5.2% of the world population (over 360 million) carry a significant hemoglobin variant [ 1 ] and in excess of 100 million beta thalassemia carriers with a global frequency of 1.5% [ 2 ]. (biomedcentral.com)
Synthesis1
- mutations that reduce alpha or beta global chain synthesis. (slideshare.net)
Deletional1
- Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. (ox.ac.uk)
Major1
- Due to remarkable success in the reduction of childhood mortality by controlling infectious diseases in developing countries, thalassemias are likely to be a major public health concern in the coming decades in South Asia. (biomedcentral.com)
Heterozygous1
- This suggests that the degree of globin chain imbalance is a significant factor in determining the red cell characteristics in heterozygous beta thalassaemia. (ox.ac.uk)
Variant1
- The present invention relates to the simultaneous and specific identification of the variant forms of α-thalassemia. (nih.gov)
Frequency2
- Accurate population frequency data are needed for planning the control of thalassaemia in the high risk Guangdong Province of southern China. (bmj.com)
- The Hb S, alpha- and beta-thalassaemia gene frequency range was 0.005-0.145, 0.01-0.40 and 0.01-0.15 respectively in various areas of Saudi Arabia. (who.int)
Beta6
- Muncie HL Jr, Campbell J. Alpha and beta thalassemia. (medscape.com)
- The dominant hemoglobin in adults (hemoglobin A) is composed of 2 alpha and 2 beta chains. (medscape.com)
- Hemoglobin has two kinds of protein chains: alpha globin and beta globin. (hoacny.com)
- The other kinds of thalassemia are alpha and beta. (indiatimes.com)
- How does beta thalassemia develop? (nih.gov)
- 13. Alpha and beta thalassemia. (nih.gov)